Single-Shot HIV Vaccine Shows Promise in Primate Study

After decades of failed attempts, researchers at The Wistar Institute have achieved something the HIV vaccine field has never seen: a single injection that produces virus-fighting antibodies within three weeks.

The team, led by Dr. Amelia Escolano, did something that seemed counterintuitive. While other scientists carefully preserved a specific sugar molecule they thought was essential for an HIV vaccine to work, Escolano's group removed it completely.

That gamble paid off. Their engineered protein, called WIN332, triggered detectable neutralizing antibodies against HIV after just one shot in nonhuman primates. A second booster increased protection even more.

"Usually, HIV vaccination protocols require seven, eight, or even ten injections to start seeing any neutralization," Escolano explained. "We injected once and already saw some neutralization."

The discovery, published in Nature Immunology, revealed something else unexpected. By removing that sugar molecule, the team found a whole new type of antibody that scientists didn't know existed. These "Type II" antibodies fight HIV differently than previously known antibodies, giving researchers another tool to work with.

Dr. Ignacio Relano-Rodriguez, the study's first author, sees practical hope in the simplified approach. "If this approach proves successful, we could potentially achieve desired immunity with just three injections," he said. "This would make vaccination protocols shorter and more affordable."

The Ripple Effect

A simpler vaccine could change everything about global HIV prevention. Fewer required doses mean lower costs, easier distribution to remote areas, and better compliance from people who struggle to complete lengthy vaccination schedules.

The research addresses a critical global need. Despite prevention advances, HIV still infects 1.3 million people annually worldwide. An effective vaccine remains the holy grail of HIV prevention, but the virus's ability to rapidly mutate has thwarted every previous attempt.

By targeting the virus in a new way and discovering previously unknown antibodies, Escolano's team has given the scientific community fresh strategies. The finding that two distinct antibody types can attack the same viral region potentially broadens protection against HIV's many different strains.

Major global health organizations have already reached out about advancing WIN332 into human clinical trials. Meanwhile, the Wistar team continues preclinical work and designs follow-up immunogens that could work together in a shortened series.

The path from promising primate results to an approved human vaccine remains long and uncertain, but this represents the kind of fundamental shift in approach that breakthrough science requires.